MA-ALIRA-HEALTH
7.1.2021 15:02:20 CET | Business Wire | Press release
Alira Health (www.alirahealth.com ), a leading international healthcare and life sciences advisory firm, announced it has acquired Chamow and Associates (www.chamowassociates.com ), a California-based integrated CMC advisory firm. This acquisition brings expertise in biologics manufacturing, quality assurance, and regulatory compliance to Alira Health’s Product Development and Regulatory practices, which now offer a full range of services, from discovery to approval, across the U.S. and EU. Chamow and Associates’ team of senior advisors complement Alira Health’s existing offerings with expertise to help clients overcome CMC challenges throughout the development process.
“Our mission at Alira Health to enable healthcare transformation and support clients in the earliest stages of development is critical to efficiently and safely shepherd innovations into the hands of patients,” said Gabriele Brambilla, Chief Executive Officer at Alira Health. “Steven Chamow has built a powerful combination of CMC capabilities, technical proficiency, and biologic expertise into his firm. We are proud to welcome them to the Alira Health family, and to offer preclinical and clinical-stage biotechnology companies a lifecycle of solutions to help bring new therapies to patients.”
"We are excited and honored to become part of the Alira Health network, and to join a talented team of experts with a complementary mission," said Dr. Steven Chamow, President of Chamow and Associates. "Becoming an Alira Health company will allow Chamow and Associates to further build our team and greatly expand our work with clients. By adding CMC expertise and advisory to Alira Health's suite of services, we have a tremendous opportunity to provide comprehensive support to meet the needs of pharmaceutical companies at any stage of the development process."
Steven Chamow will become Alira Health’s Senior Vice President, CMC Development and will lead biopharmaceutical product development.
Lighthouse BioPartners acted as a financial advisor to Chamow and Associates for this transaction.
About Chamow and Associates:
Chamow and Associates is a leading biopharmaceutical consulting company based in the San Francisco Bay Area. Since 2008, the company has provided integrated CMC services, including molecular engineering, process development and manufacturing, quality, regulatory, and project management services, to clinical-stage biotechnology companies around the world. Chamow and Associates focuses on monoclonal antibodies and derivatives, including bispecific antibodies and antibody drug conjugates, in addition to other recombinant protein products.
Learn more at https://chamowassociates.com/ .
About Alira Health:
Alira Health is an international advisory firm on the frontlines of healthcare transformation. We provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their solutions lifecycle.
Alira Health was founded in 1999 and is based in Framingham, MA, U.S. Offices are located in San Francisco, CA, U.S.; Paris, France; Barcelona, Spain; Munich, Germany; Milan, Italy; and Basel and Geneva, Switzerland.
Learn more at https://www.alirahealth.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005076/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium25.3.2026 23:22:00 CET | Press release
The General Directorate of Passports, together with the Presidency of the Dominican Republic, are leading the transformation of the country’s passport issuance system with a new, secure, efficient document aligned with international standards.In 2025, the Thales-MIDAS consortium was awarded the contract to develop, issue, and personalize a modern, secure, and highly reliable travel document for Dominican citizens, incorporating additional cybersecurity measures. The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and M
3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release
Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst
Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release
Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the
ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 14:30:00 CET | Press release
Strategic LAX gateway enables faster, predictable cargo movement through a reimagined sea–air logistics model ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Re
Incyte Announces Executive Leadership Appointments25.3.2026 14:00:00 CET | Press release
Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom